Overview

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Status:
Completed

Trial end date:
2009-10-07

Target enrollment:

Participant gender:

Summary

The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe Ltd.

Treatments:

Tacrolimus